Australia markets open in 2 hours 42 minutes
  • ALL ORDS

    7,717.10
    -80.40 (-1.03%)
     
  • AUD/USD

    0.7210
    -0.0071 (-0.98%)
     
  • ASX 200

    7,393.90
    -80.50 (-1.08%)
     
  • OIL

    84.27
    +2.15 (+2.62%)
     
  • GOLD

    1,817.30
    -4.10 (-0.23%)
     
  • BTC-AUD

    59,454.56
    -1,323.35 (-2.18%)
     
  • CMC Crypto 200

    1,037.76
    +12.03 (+1.17%)
     

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BeyondSpring Inc. - BYSI

·2-min read

NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BeyondSpring Inc. (“BeyondSpring” or the “Company”) (NASDAQ: BYSI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether BeyondSpring and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On December 1, 2021, BeyondSpring issued a press release “announc[ing] it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN). The FDA issued the CRL to indicate that they have completed their review of the application and have determined that it cannot be approved in its present form.” BeyondSpring stated that “[t]he FDA’s CRL indicated that the results of the single registrational trial (106 Phase 3) was not sufficiently robust to demonstrate benefit and that a second well controlled trial would be required to satisfy the substantial evidence requirement to support the CIN indication.”

On this news, BeyondSpring’s stock price fell $7.84 per share, or 61.39% to close at $4.93 per share on December 1, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting